The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro
ConclusionThus, in OSCC cells in vitro, inhibition of EGFR activity with gefitinib enhances the apoptotic effect of cisplatin. This has potential implications for enhancement of cisplatin effectiveness in tumors that over-express the EGFR.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Oral Cancer | Skin Cancer | Squamous Cell Carcinoma | Study